Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Barrett Esophagus
Interventions: Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more

Conditions: Systemic Lupus Erythematosus
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions: AAV2-hAADC; Drug
Lead sponsor: Russell Lonser; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Phenytoin (brand name Dilantin), Hydrocortisone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions: KRT-232, Cytarabine, Decitabine; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: ANCA-associated Vasculitis
Interventions: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Colon Cancer, Colorectal Carcinoma, Colon Cleansing
Interventions: NER1006, Trisulfate solution; Drug
Lead sponsor: Norgine; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Annapolis, Maryland • Chevy Chase, Maryland + 9 more

Conditions: Chronic Gout
Interventions: SEL-212 low-dose, SEL-212 high-dose, Normal Saline; Drug · Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more

Conditions: Low Vision Aids
Interventions: Tactile Labels for Drug identity and dose frequency; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions: MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492; Procedure · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 18 more

Conditions: Triglycerides
Interventions: Curcumin (Longvida™), Half Dose Curcumin (Longvida™), Astaxanthin, Placebo Control; Dietary Supplement · Other
Lead sponsor: Medinutra LLC; Other
Eligibility: 21 Years to 59 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2); Biological · Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions: methylprednisolone (IVMP), methylprednisolone (two doses IVMP); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Up to 30 Days
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Rhinitis, Sinusitis
Interventions: Quinine Sulfate, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease, Hypogonadism
Interventions: AndroGel (Solvay Pharmaceuticals); Drug
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 55 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
Interventions: Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost; Procedure · Radiation
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atherosclerosis
Interventions: SB 480848, tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more

Conditions: Hypophosphatasia
Interventions: asfotase alfa; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: St Louis, Missouri • Durham, North Carolina

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: ADHD - Inattentive Type, ADHD - Combined Type
Interventions: OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Years to 11 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Ablation of Intestinal Metaplasia Containing Dysplasia

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

AAV2-hAADC for Parkinson's Disease (PDCS-01)

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Fluid Chloride and AKI in Cardiopulmonary Bypass

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Tactile Low Vision Labeling of Ophthalmic Drops

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Topical Irrigation Therapy for CRS

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

A Study To Determine The Effect Of SB-480848 On Asthma

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Belimumab With Rituximab for Primary Membranous Nephropathy

Attention Deficit Disorder Medication Response Study